Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Product quality issue? 484 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 484 reports of Product quality issue have been filed in association with MEPOLIZUMAB (Nucala). This represents 1.1% of all adverse event reports for MEPOLIZUMAB.

484
Reports of Product quality issue with MEPOLIZUMAB
1.1%
of all MEPOLIZUMAB reports
457
Deaths
374
Hospitalizations

How Dangerous Is Product quality issue From MEPOLIZUMAB?

Of the 484 reports, 457 (94.4%) resulted in death, 374 (77.3%) required hospitalization, and 388 (80.2%) were considered life-threatening.

Is Product quality issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 484 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Product quality issue?

ETONOGESTREL (4,651) ALBUTEROL (4,466) TIOTROPIUM (3,821) MOMETASONE FUROATE (3,406) LIDOCAINE (3,126) FLUTICASONE\SALMETEROL (2,986) FORMOTEROL\MOMETASONE FUROATE (2,458) FENTANYL (2,450) NICOTINE (1,987) EXENATIDE (1,839)

Which MEPOLIZUMAB Alternatives Have Lower Product quality issue Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Product quality issue Reports All Drugs Causing Product quality issue MEPOLIZUMAB Demographics